Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor. It affects intrinsic apoptotic and MAPK signaling pathways by binding to anti-apoptotic Bcl-2/Bcl-xL proteins to release pro-apoptotic factors, effectively promoting apoptosis and clearing senescent and cancer cells.
Navitoclax (ABT-263) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Navitoclax (ABT-263) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.